首页> 美国卫生研究院文献>Filaria Journal >Evaluation of the efficacy of ProHeart® 6 (moxidectin) against a resistant isolate of Dirofilaria immitis (JYD-34) in dogs
【2h】

Evaluation of the efficacy of ProHeart® 6 (moxidectin) against a resistant isolate of Dirofilaria immitis (JYD-34) in dogs

机译:评估ProHeart®6(莫昔克丁)对犬抗丝虫病抗性分离株(JYD-34)的功效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundIn a previous study, it was demonstrated that ProHeart® 6 (PH6) (moxidectin, Zoetis) provided only about 20% efficacy in a small six-dog study against a macrocyclic lactone –resistant Dirofilaria immitis isolate (Jd2009–2) when dogs were inoculated with infective third-stage larvae (L3) at the end of the dosing period (ie, 180 days post treatment). The objective of the current study was to determine the prophylactic efficacy of a moxidectin sustained-release formulation (PH6) against a confirmed macrocyclic lactone–resistant isolate of D. immitis (JYD-34) in dogs when administered by subcutaneous injection at the labeled dose of 0.17 mg/kg 2 days before L3 inoculation. This was intended to model the scenario where dogs become infected with resistant heartworms at the end of the PH6 treatment period (ie, 6 months post treatment) when dogs would routinely be given another injection under normal field use.
机译:背景在以前的研究中,已证明ProHeart ® 6(PH6)(moxidectin,Zoetis)在一项针对大环内酯耐药的Dirofilaria炎性肠炎隔离株的小型六只狗研究中仅提供约20%的功效( Jd2009–2),在给药期结束时(即治疗后180天),给犬接种了感染性第三阶段幼虫(L3)。本研究的目的是确定当以标记剂量通过皮下注射给药时,莫昔克丁缓释制剂(PH6)对犬中确诊的耐大环内酯的D. Immitis分离株(JYD-34)的预防作用L3接种前2天剂量为0.17 mg / kg。这旨在模拟在PH6治疗期结束时(即治疗后6个月)狗在常规田间使用下常规再次注射时感染抗性丝虫的情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号